patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_960218 | REC_0013301 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 9.6 | 79 | female | 2 | 20 | 5.8 | 2 | osimertinib 80 mg daily | 19.7 | true | MSS | 2026-03-15T05:36:00.336699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_828803 | REC_0013302 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 6.9 | 73 | female | 1 | 15 | 6 | 5 | alectinib 600 mg BID | 4.1 | false | MSS | 2026-03-15T05:36:00.337074+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622061 | REC_0013303 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 11.7 | 73 | female | 2 | 21 | 3.7 | 4 | entrectinib 600 mg daily | 16.5 | true | MSS | 2026-03-15T05:36:00.337407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_636836 | REC_0013304 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 7.1 | 71 | female | 1 | 14 | 7 | 2 | sotorasib 960 mg daily | 23.4 | false | MSS | 2026-03-15T05:36:00.337760+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796108 | REC_0013305 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 13.2 | 59 | female | 1 | 22 | 4.8 | 3 | entrectinib 600 mg daily | 8.1 | false | MSS | 2026-03-15T05:36:00.338108+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857353 | REC_0013306 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 12.2 | 73 | female | 2 | 20 | 7.3 | 2 | sotorasib 960 mg daily | 18.3 | true | MSS | 2026-03-15T05:36:00.338460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105277 | REC_0013307 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 12 | 7.9 | 82 | female | 2 | 20 | 5.3 | 2 | sotorasib 960 mg daily | 18.8 | true | MSS | 2026-03-15T05:36:00.338792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226140 | REC_0013308 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 13.9 | 76 | female | 1 | 12 | 5.5 | 4 | entrectinib 600 mg daily | 9.8 | false | MSS | 2026-03-15T05:36:00.339113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581001 | REC_0013309 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 13.4 | 72 | male | 2 | 21 | 4 | 7 | entrectinib 600 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:36:00.339426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941185 | REC_0013310 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 9.1 | 57 | female | 0 | 27 | 4.3 | 2 | osimertinib 80 mg daily | 22.6 | false | MSS | 2026-03-15T05:36:00.339735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890789 | REC_0013311 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 10.2 | 80 | female | 1 | 16 | 5.3 | 6 | pembrolizumab 200 mg q3w | 7.8 | true | MSS | 2026-03-15T05:36:00.340052+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394813 | REC_0013312 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 12.1 | 63 | female | 0 | 4 | 3.5 | 3 | osimertinib 80 mg daily | 11.7 | true | MSS | 2026-03-15T05:36:00.340769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126163 | REC_0013313 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.9 | 62 | female | 1 | 67 | 4.2 | 5 | pembrolizumab 200 mg q3w | 16.7 | false | MSS | 2026-03-15T05:36:00.341345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807237 | REC_0013314 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.9 | 73 | female | 2 | 2 | 6 | 5 | entrectinib 600 mg daily | 11.9 | false | MSI-H | 2026-03-15T05:36:00.341733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927993 | REC_0013315 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 12.4 | 73 | female | 3 | 16 | 4.6 | 3 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:36:00.342107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776727 | REC_0013316 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 13.1 | 75 | female | 2 | 20 | 9.1 | 2 | osimertinib 80 mg daily | 20.8 | false | MSS | 2026-03-15T05:36:00.342401+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980469 | REC_0013317 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 35 | 13.1 | 72 | male | 2 | 20 | 6 | 4 | osimertinib 80 mg daily | 13.9 | false | MSS | 2026-03-15T05:36:00.342694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998835 | REC_0013318 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 16.9 | 65 | male | 0 | 27 | 5.6 | 5 | osimertinib 80 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:00.342993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254096 | REC_0013319 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 8.3 | 53 | female | 0 | 18 | 5.8 | 1 | osimertinib 80 mg daily | 14.7 | false | MSS | 2026-03-15T05:36:00.343280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549419 | REC_0013320 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.7 | 69 | male | 0 | 18 | 4.7 | 3 | sotorasib 960 mg daily | 7.8 | false | MSS | 2026-03-15T05:36:00.343575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228328 | REC_0013321 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 10.6 | 72 | female | 2 | 4 | 7.8 | 8 | pembrolizumab 200 mg q3w | 5.7 | true | MSI-H | 2026-03-15T05:36:00.343861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376101 | REC_0013322 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 15.6 | 71 | female | 1 | 11 | 5.9 | 2 | osimertinib 80 mg daily | 25.7 | false | MSI-H | 2026-03-15T05:36:00.344193+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368791 | REC_0013323 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 22 | 19.7 | 67 | male | 0 | 10 | 5.8 | 0 | entrectinib 600 mg daily | 30.6 | true | MSI-H | 2026-03-15T05:36:00.344511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381679 | REC_0013324 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 2.2 | 75 | female | 1 | 91 | 3.3 | 1 | pembrolizumab 200 mg q3w | 22.2 | true | MSS | 2026-03-15T05:36:00.344791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805181 | REC_0013325 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.3 | 57 | female | 0 | 21 | 6.9 | 5 | osimertinib 80 mg daily | 7.6 | true | MSS | 2026-03-15T05:36:00.345078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221917 | REC_0013326 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 6.8 | 70 | female | 0 | 64 | 4.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.3 | false | MSS | 2026-03-15T05:36:00.345463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597023 | REC_0013327 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15.5 | 59 | male | 0 | 11 | 6.8 | 5 | entrectinib 600 mg daily | 14 | true | MSI-H | 2026-03-15T05:36:00.345773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158535 | REC_0013328 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 7.4 | 62 | female | 1 | 19 | 5 | 1 | osimertinib 80 mg daily | 20.4 | true | MSS | 2026-03-15T05:36:00.346067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_624587 | REC_0013329 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 8.5 | 86 | female | 1 | 19 | 6.4 | 1 | alectinib 600 mg BID | 17.6 | true | MSS | 2026-03-15T05:36:00.346363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861403 | REC_0013330 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 7.7 | 70 | male | 1 | 54 | 7 | 3 | carboplatin + paclitaxel + pembrolizumab | 17.9 | false | MSS | 2026-03-15T05:36:00.346656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364059 | REC_0013331 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.4 | 82 | female | 3 | 26 | 5.7 | 7 | entrectinib 600 mg daily | 12.2 | false | MSS | 2026-03-15T05:36:00.347037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929515 | REC_0013332 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 18 | 90 | male | 1 | 18 | 2.9 | 6 | sotorasib 960 mg daily | 11.6 | false | MSS | 2026-03-15T05:36:00.347390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965675 | REC_0013333 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.3 | 69 | female | 0 | 9 | 3.8 | 6 | alectinib 600 mg BID | 13.3 | true | MSS | 2026-03-15T05:36:00.347762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628814 | REC_0013334 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 2.2 | 88 | male | 1 | 16 | 3.7 | 9 | sotorasib 960 mg daily | 5.5 | false | MSS | 2026-03-15T05:36:00.348138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855854 | REC_0013335 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 16.6 | 61 | male | 0 | 24 | 5.5 | 6 | entrectinib 600 mg daily | 7 | false | MSS | 2026-03-15T05:36:00.348524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_424539 | REC_0013336 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 12.6 | 79 | female | 1 | 15 | 6.1 | 4 | sotorasib 960 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:36:00.348880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255754 | REC_0013337 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 15 | 13.4 | 60 | female | 0 | 12 | 4.5 | 2 | alectinib 600 mg BID | 26.8 | false | MSI-H | 2026-03-15T05:36:00.349222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340273 | REC_0013338 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 34 | 9.2 | 57 | female | 0 | 9 | 3.7 | 7 | osimertinib 80 mg daily | 14.9 | false | MSS | 2026-03-15T05:36:00.349528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525300 | REC_0013339 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.8 | 79 | female | 2 | 14 | 5.4 | 6 | osimertinib 80 mg daily | 6.5 | false | MSS | 2026-03-15T05:36:00.349978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878515 | REC_0013340 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 32 | 5.4 | 70 | female | 1 | 19 | 3.9 | 2 | pembrolizumab 200 mg q3w | 23.4 | false | MSS | 2026-03-15T05:36:00.350318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796478 | REC_0013341 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 14.3 | 75 | female | 2 | 23 | 3.8 | 2 | pembrolizumab 200 mg q3w | 21.3 | false | MSS | 2026-03-15T05:36:00.350621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106465 | REC_0013342 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.8 | 73 | female | 1 | 53 | 5.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.5 | false | MSS | 2026-03-15T05:36:00.350928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235410 | REC_0013343 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 13 | 7.6 | 56 | female | 1 | 9 | 6.4 | 1 | entrectinib 600 mg daily | 10.6 | false | MSS | 2026-03-15T05:36:00.351236+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808105 | REC_0013344 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.4 | 65 | male | 1 | 15 | 6.8 | 4 | alectinib 600 mg BID | 6.1 | true | MSS | 2026-03-15T05:36:00.351538+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698461 | REC_0013345 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 9.1 | 59 | female | 0 | 14 | 4.9 | 1 | osimertinib 80 mg daily | 16.8 | false | MSS | 2026-03-15T05:36:00.351828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520822 | REC_0013346 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 12.7 | 72 | female | 1 | 11 | 6.4 | 2 | sotorasib 960 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:36:00.352173+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751395 | REC_0013347 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 12.8 | 69 | male | 0 | 19 | 3 | 6 | osimertinib 80 mg daily | 6.2 | false | MSS | 2026-03-15T05:36:00.352532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442570 | REC_0013348 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 10.2 | 46 | male | 0 | 14 | 6.7 | 4 | sotorasib 960 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:36:00.352843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345664 | REC_0013349 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 12 | 72 | female | 1 | 11 | 6.2 | 1 | pembrolizumab 200 mg q3w | 15.4 | false | MSS | 2026-03-15T05:36:00.353147+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965841 | REC_0013350 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 14.1 | 73 | female | 0 | 12 | 5.6 | 4 | entrectinib 600 mg daily | 10.8 | false | MSS | 2026-03-15T05:36:00.353444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550851 | REC_0013351 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 11.2 | 71 | female | 1 | 17 | 6.2 | 6 | osimertinib 80 mg daily | 12.4 | false | MSI-H | 2026-03-15T05:36:00.353739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538127 | REC_0013352 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 7.8 | 67 | female | 1 | 15 | 4 | 6 | entrectinib 600 mg daily | 13.2 | true | MSS | 2026-03-15T05:36:00.354180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_733155 | REC_0013353 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 6.4 | 66 | female | 0 | 41 | 4.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.8 | false | MSS | 2026-03-15T05:36:00.354510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592682 | REC_0013354 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 15 | 15.8 | 70 | female | 1 | 25 | 6.3 | 0 | osimertinib 80 mg daily | 35.7 | false | MSS | 2026-03-15T05:36:00.354810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381547 | REC_0013355 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 13.1 | 71 | female | 2 | 13 | 5.4 | 8 | entrectinib 600 mg daily | 16.6 | true | MSS | 2026-03-15T05:36:00.355106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224240 | REC_0013356 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.7 | 72 | female | 1 | 34 | 6.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 7 | true | MSS | 2026-03-15T05:36:00.355415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879449 | REC_0013357 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 12.3 | 62 | female | 0 | 25 | 7.5 | 1 | sotorasib 960 mg daily | 29.4 | false | MSS | 2026-03-15T05:36:00.355728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961896 | REC_0013358 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 8.8 | 61 | female | 0 | 60 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 13 | false | MSS | 2026-03-15T05:36:00.356018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277728 | REC_0013359 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 12.6 | 62 | male | 0 | 18 | 3.5 | 2 | osimertinib 80 mg daily | 24.1 | true | MSS | 2026-03-15T05:36:00.356849+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924939 | REC_0013360 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.2 | 60 | female | 1 | 35 | 4.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.4 | true | MSS | 2026-03-15T05:36:00.357198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355677 | REC_0013361 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 5.3 | 59 | male | 0 | 1 | 5.5 | 1 | pembrolizumab 200 mg q3w | 16.8 | false | MSS | 2026-03-15T05:36:00.357521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616790 | REC_0013362 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 14.8 | 81 | female | 3 | 15 | 5.9 | 7 | osimertinib 80 mg daily | 14.7 | true | MSS | 2026-03-15T05:36:00.357813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888096 | REC_0013363 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 31 | 13.2 | 67 | male | 1 | 9 | 5.9 | 0 | sotorasib 960 mg daily | 57.9 | true | MSS | 2026-03-15T05:36:00.358107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797793 | REC_0013364 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 14.4 | 80 | female | 2 | 18 | 4.2 | 2 | sotorasib 960 mg daily | 22.9 | true | MSS | 2026-03-15T05:36:00.358407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644024 | REC_0013365 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 14.8 | 60 | male | 0 | 25 | 5.5 | 4 | alectinib 600 mg BID | 5.9 | true | MSI-H | 2026-03-15T05:36:00.358884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148312 | REC_0013366 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 17.2 | 71 | female | 0 | 22 | 6.2 | 1 | osimertinib 80 mg daily | 22.2 | true | MSI-H | 2026-03-15T05:36:00.359263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333026 | REC_0013367 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 16 | 67 | female | 0 | 9 | 5.2 | 5 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:36:00.359602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648956 | REC_0013368 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.2 | 85 | male | 1 | 11 | 5.6 | 2 | entrectinib 600 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:36:00.359937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148438 | REC_0013369 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 15 | 73 | female | 2 | 19 | 4 | 3 | pembrolizumab 200 mg q3w | 11.4 | true | MSS | 2026-03-15T05:36:00.360967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461557 | REC_0013370 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 6.8 | 61 | female | 0 | 8 | 5.4 | 2 | alectinib 600 mg BID | 14.9 | false | MSS | 2026-03-15T05:36:00.361335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603601 | REC_0013371 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 31 | 5.7 | 60 | male | 0 | 38 | 5.6 | 2 | pembrolizumab 200 mg q3w | 9.7 | false | MSS | 2026-03-15T05:36:00.361649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380977 | REC_0013372 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 7.8 | 54 | female | 0 | 23 | 4.9 | 6 | pembrolizumab 200 mg q3w | 10.7 | false | MSS | 2026-03-15T05:36:00.361967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252700 | REC_0013373 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.6 | 67 | female | 1 | 22 | 4.1 | 8 | carboplatin + paclitaxel + pembrolizumab | 8.3 | true | MSS | 2026-03-15T05:36:00.362268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681939 | REC_0013374 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 6.3 | 66 | female | 1 | 12 | 9 | 2 | sotorasib 960 mg daily | 15.2 | true | MSS | 2026-03-15T05:36:00.362560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_742590 | REC_0013375 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.7 | 64 | male | 0 | 12 | 5.3 | 5 | osimertinib 80 mg daily | 4.9 | false | MSI-H | 2026-03-15T05:36:00.362866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950770 | REC_0013376 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 7.6 | 71 | male | 1 | 11 | 5.7 | 2 | osimertinib 80 mg daily | 27.8 | false | MSS | 2026-03-15T05:36:00.363168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736908 | REC_0013377 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 10.2 | 59 | male | 1 | 8 | 6.3 | 2 | sotorasib 960 mg daily | 21.1 | false | MSS | 2026-03-15T05:36:00.363493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515275 | REC_0013378 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 9.7 | 78 | female | 3 | 11 | 6.5 | 1 | alectinib 600 mg BID | 22.3 | false | MSS | 2026-03-15T05:36:00.363984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560309 | REC_0013379 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 14.4 | 54 | male | 0 | 10 | 6 | 2 | osimertinib 80 mg daily | 6.1 | true | MSS | 2026-03-15T05:36:00.364723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631573 | REC_0013380 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 20.6 | 72 | female | 1 | 6 | 3 | 4 | osimertinib 80 mg daily | 8.4 | true | MSI-H | 2026-03-15T05:36:00.365136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243929 | REC_0013381 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 13.3 | 74 | female | 1 | 15 | 5.2 | 2 | sotorasib 960 mg daily | 8.3 | true | MSI-H | 2026-03-15T05:36:00.365497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587033 | REC_0013382 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.2 | 76 | female | 2 | 20 | 7.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.8 | false | MSS | 2026-03-15T05:36:00.365837+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358484 | REC_0013383 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 6.1 | 67 | female | 0 | 10 | 7.6 | 1 | pembrolizumab 200 mg q3w | 19 | true | MSS | 2026-03-15T05:36:00.366700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415883 | REC_0013384 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 7.7 | 65 | female | 0 | 43 | 5.5 | 8 | pembrolizumab 200 mg q3w | 8.4 | false | MSS | 2026-03-15T05:36:00.367107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301417 | REC_0013385 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 7.5 | 78 | female | 2 | 18 | 4.6 | 9 | alectinib 600 mg BID | 10.9 | false | MSS | 2026-03-15T05:36:00.367525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359768 | REC_0013386 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 9.2 | 64 | male | 0 | 11 | 7.1 | 4 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:36:00.367858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289612 | REC_0013387 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.7 | 75 | female | 2 | 22 | 3.5 | 5 | osimertinib 80 mg daily | 11.7 | true | MSS | 2026-03-15T05:36:00.368283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558597 | REC_0013388 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 4.9 | 65 | male | 1 | 14 | 5.3 | 0 | osimertinib 80 mg daily | 11.2 | true | MSS | 2026-03-15T05:36:00.368652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477341 | REC_0013389 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 3.8 | 65 | male | 1 | 76 | 7.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 31.5 | true | MSS | 2026-03-15T05:36:00.368976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881568 | REC_0013390 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 12.2 | 55 | male | 1 | 6 | 4.7 | 1 | osimertinib 80 mg daily | 21.7 | true | MSS | 2026-03-15T05:36:00.369271+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712388 | REC_0013391 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 13.4 | 64 | male | 1 | 14 | 3.3 | 1 | entrectinib 600 mg daily | 12.4 | false | MSI-H | 2026-03-15T05:36:00.369762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510929 | REC_0013392 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 7.3 | 50 | female | 0 | 15 | 6.5 | 2 | pembrolizumab 200 mg q3w | 20.9 | true | MSS | 2026-03-15T05:36:00.370143+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725211 | REC_0013393 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13 | 67 | female | 0 | 22 | 3.8 | 4 | alectinib 600 mg BID | 6.9 | true | MSS | 2026-03-15T05:36:00.370509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536569 | REC_0013394 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 6.8 | 74 | female | 3 | 20 | 5.8 | 8 | alectinib 600 mg BID | 17.3 | true | MSS | 2026-03-15T05:36:00.370849+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812333 | REC_0013395 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 11.8 | 53 | male | 0 | 21 | 4.8 | 2 | sotorasib 960 mg daily | 13 | false | MSS | 2026-03-15T05:36:00.371221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593400 | REC_0013396 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 12.8 | 67 | female | 0 | 7 | 6.6 | 8 | sotorasib 960 mg daily | 8.5 | false | MSI-H | 2026-03-15T05:36:00.371567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871419 | REC_0013397 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 5.5 | 77 | female | 1 | 25 | 6.4 | 7 | osimertinib 80 mg daily | 7.9 | false | MSS | 2026-03-15T05:36:00.371892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853223 | REC_0013398 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12.3 | 66 | female | 1 | 14 | 5.4 | 1 | alectinib 600 mg BID | 9.1 | false | MSS | 2026-03-15T05:36:00.375602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604680 | REC_0013399 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 15.1 | 75 | female | 2 | 10 | 6.4 | 3 | osimertinib 80 mg daily | 4.5 | false | MSS | 2026-03-15T05:36:00.376158+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430842 | REC_0013400 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 2 | 72 | female | 2 | 15 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.3 | true | MSS | 2026-03-15T05:36:00.376762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.